麻豆传媒

Professor Dennin earned his A. B. from Princeton University, and his M.A. and Ph.D. from the University of California, Santa Barbara. He held a postdoctoral position at UCLA. He is an Alfred P. Sloan Research Fellow and a Research Corporation Cottrell Scholar. 

Professor Dennin's main research interest is systems that exhibit emergent properties. These include the behavior of complex fluids, such as foam and sand, as well as the complex dynamics of biological systems. 

Professor Dennin is well-known for popularizing science for the public. He has taught many online courses on the nature of science, including team teaching a MOOC based on the television program, The Walking Dead. He has appeared on a number of television programs, including Spider-man Tech, Batman Tech, Star Wars Tech, and Ancient Aliens. 

William S. Raoofi, M.D., is a pain management specialist with The Center for Interventional Pain Medicine at Mercy Medical Center in Baltimore. Dr. William Raoofi utilizes leading-edge treatment options to alleviate and manage chronic pain in patients caused by cancer, orthopedic disorders and related conditions

Dr. William Raoofi is a fellowship-trained physician in Interventional Pain Management. He completed specialized training in the evaluation, diagnosis, and treatment of patients experiencing chronic pain and related symptoms. He utilizes the Center鈥檚 state-of-the-art imaging and diagnostic equipment, along with minimally invasive treatment procedures and techniques to alleviate pain.

Dr. Raoofi has a special interest in neuromodulation 鈥� a form of pain reduction therapy that utilizes technological devices that alter pain signaling in the body to reduce pain and improve function. These types of therapies may include Dorsal Root Ganglion (DRG) Stimulation, Peripheral Nerve Stimulation, and Spinal Cord Stimulation.

Dr. Foster is Senior Scientist and Distinguished Fellow, and also director of the Data Science and Learning Division, at Argonne National Laboratory, and the Arthur Holly Compton Distinguished Service Professor of Computer Science at the University of Chicago. His research deals with distributed, parallel, and data-intensive computing technologies, and innovative applications of those technologies to scientific problems in such domains as materials science, climate change, and biomedicine. He is a fellow of the AAAS, ACM, BCS, and IEEE, and an Office of Science Distinguished Scientists Fellow. His awards include the BCS Lovelace Medal and IEEE Babbage and Kanai awards.

Rachana Ananthakrishnan is Executive Director & Head of Products at the University of Chicago, and has a Joint Staff Appointment at Argonne National Laboratory.  In her role at the university, she leads the Globus (www.globus.org) department, which delivers a research data management platform to national and international research institutions. She also serves on the WestGrid Board of Directors, and is a member of the InCommon Community Assurance and Trust Board. 

Her work is focused on the research and education field, and she has worked on security and data management solutions on various projects including Earth System Grid (ESG), Biomedical Informatics Research Network (BIRN) and Extreme Science and Engineering Discovery Environment (XSEDE). Prior to that she worked on the Globus Toolkit engineering and customer engagement teams, leading the efforts in web services and security technologies. Rachana received her MS in Computer Science at Indiana University, Bloomington.

Vas is the 鈥渃ustomer guy鈥� at Globus, the de facto standard platform for research data management, developed and operated by the University of Chicago. He is also a lecturer in the Masters Program in Computer Science at the University, where he teaches courses on Cloud Computing and Product Management. Vas has over 30 years of experience in operational and consulting roles, spanning strategy, marketing and technology, and was instrumental in bringing many emerging technologies as products to market. He consults with both global enterprises and early stage technology startups on product management and go-to-market strategy. https://www.linkedin.com/in/vasiliadis/

Cohen began studying multiple sclerosis (MS) in the 1980s when it was still considered an untreatable disease. Today, 15 disease-modifying treatments are approved for MS, and Cohen said he has 鈥渂een involved in some way or another鈥� with the development of each of them.

Cohen has worked with ACTRIMS since its founding in 1995. The group is made up of clinicians and researchers across North America who focus on sharing knowledge in hopes of improving MS treatment options and providing training to early-career physicians and scientists. It has counterparts in other areas of the world, including the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

During his residency, which began in 1981, Cohen was drawn to neuroscience and immunology, both fields than in their infancies and both notoriously complex. 鈥淢S is a field where those two topics intersect,鈥� he told Multiple Sclerosis 麻豆传媒 Today.

He came to the Mellen Center in 1994, just one year after the first disease-modifying treatment, Betaseron (interferon beta 1b, marketed by Bayer HealthCare), was approved for MS. He treats a large population of MS patients there and was named director of its Experimental Therapeutics Program in 2014. He designs and runs clinical trials for MS and related diseases, while training other specialists in the skills necessary to run MS trials.

As of July 1, 2019 Benjamin M. Segal, MD, assumed the roles of chair of the Department of Neurology and Director of the Neurological Research Institute at The Ohio State University College of Medicine. He is also co-director of The Ohio State University Wexner Medical Center鈥檚 Neurological Institute. He earned his medical degree Brown University, completed his internship in medicine at University of Chicago and conducted his residency in neurology at New York Hospital/Weill Medical College of Cornell University.

Dr. Segal began his academic career at the National Institutes of Health (NIH), where he conducted innovative research in multiple sclerosis and immunology. In 2000, he was recruited to the Department of Neurology at the University of Rochester. That year he was awarded the prestigious Harry Weaver Neuroscience Scholar award by the National Multiple Sclerosis Society. The University of Michigan鈥攈ome to one of our nation鈥檚 top neurology programs鈥攔ecruited Dr. Segal to lead its Division of Multiple Sclerosis in 2007. Under Dr. Segal鈥檚 leadership, the University of Michigan became a national referral center for the treatment of patients with multiple sclerosis. The MS clinic population expanded in size from approximately 400 to 4,000 patients during his tenure.

Dr. Segal is internationally recognized for his work in multiple sclerosis (MS) and neuroimmunology. With annual NIH funding for his ongoing research programs in excess of 1.3 million dollars, his discoveries have contributed to the basic understanding of the pathogenesis of multiple sclerosis (MS) and similar diseases. He has shown that the type of inflammation that causes damage to the nervous system during MS can vary among individuals, suggesting that pharmaceutical regimens must be personalized for each patient. Dr. Segal has directed a number of industry- and government-sponsored clinical trials and biomarker studies that focus on individuals with relapsing and progressive forms of the disease. More recently, his laboratory is investigating how destructive immune responses in the nervous system can be skewed and redirected to initiate repair. He publishes in high impact academic journals, including the Journal of Clinical Investigation,Annals of Neurology, Proceedings of the National Academy of Sciences of the United States of America, and Lancet Neurology.

Dr. Segal has received innumerable awards, lectured nationally and internationally and served on multiple NIH study sections, including co-chairing the major review panel in his field. He holds several patents and is a member of every major organization in neurology. Dr. Segal served as Program Chair for the annual meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) between 2016 and 2018, and he currently serves as a Director at ACTRIMS. Through ACTRIMS, he has developed an annual national symposium to educate neurology residents and young research investigators about the diagnosis, pathogenesis, and treatment of MS. Dr. Segal was inducted into the University of Michigan League of Research Excellence in 2014. He was a Senior Scholar of the A. Alfred Taubman Medical Research Institute and has been named among the Best Doctors in America for the past eight years.

Johanna Schoen (Ph.D. Univ. of North Carolina, 1996) is a professor in the Department of History. Her major interests are the history of women and medicine, the history of reproductive rights, and the history of sexuality. Her research traces women鈥檚 health and reproductive care through the twentieth century. Her first book, Choice and Coercion: Birth Control, Sterilization, and Abortion in Public Health and Welfare, examines the role which birth control, sterilization, and abortion played in public health and welfare policies between the 1920s and the 1970s.

In 2002, she shared her research on the history of eugenic sterilization in North Carolina with a journalist from the Winston Salem Journal. North Carolina鈥檚 sterilization program ran from the 1920s to the 1970s and led to the sterilization of more than 7,000 people. The paper ran a week-long series of articles on the subject which ultimately resulted in an official apology by the governor of North Carolina. In 2007, Schoen designed an exhibit on North Carolina鈥檚 eugenic sterilization program which opened that year in the North Carolina Museum of History in Raleigh. In 2014, North Carolina began to pay  restitution to sterilization victims 鈥� the first state in the country to take such a step. 

Schoen鈥檚 second book, Abortion After Roe, which won the William H. Welch Medal for the best book in the history of medicine by the American Association for the History of Medicine, traces the history of abortion since legalization. Abortion is 鈥� and always has been 鈥� an arena for contesting power relations between women and men. When in 1973 the Supreme Court made the procedure legal throughout the United States, it seemed that women were at last able to make decisions about their own bodies. In the four decades that followed, however, abortion became ever more politicized and stigmatized. Abortion After Roe chronicles and analyzes what the new legal status and changing political environment have meant for abortion providers and their patients. It sheds light on the little-studied experience of performing and receiving abortion care from the 1970s 鈥� a period of optimism 鈥� to the rise of the antiabortion movement and the escalation of antiabortion tactics in the 1980s to the 1990s and beyond, when violent attacks on clinics and abortion providers led to a new articulation of abortion care as moral work. More than four decades after the legalization of abortion, the abortion provider community has powerfully asserted that abortion care is a moral good.

For decades, Schoen has worked with abortion providers to preserve the history of legal abortion in the United States and to use historical analysis and insights to help preserve access to abortion care. Her current work explores ethical frameworks in defense of the right to decide over life and death in abortion care, neonatology, and at the end of life in so-called physician assisted deaths.

With Kim Mutcherson from the Rutgers Law School at Camden, she is co-directing the Rutgers Center for Historical Analysis Life and Death Seminar from 2019-2021.

In her spare time, she volunteers at Memorial Sloan Kettering Cancer Center where she is a member of the Patient and Family Advisory Counsel for Quality and the Ethics Committee and works on improving end-of-life conversations between clinicians, patients, and caregivers.

Stephen Crystal (Ph. D., Harvard, 1981) is a Research Professor and Chair of the AIDS Policy Research Group at the Institute. He directs the Center for Health Services Research, focusing on pharmacotherapy, chronic disease management, and outcomes, as well as the Center for Health Services Research Development, funded under a grant from the Agency for Healthcare Policy and Research and Quality (AHRQ). Dr. Crystal also serves as Associate Director for Research of the Center for State Health Policy. Dr. Crystal鈥檚 research group conducts a variety of studies addressing use, access, costs and outcomes of health care services, as well as research on policies and programs affecting the elderly. The group has published extensively on HIV treatment and on health care for the elderly. A growing area of the group鈥檚 work in recent years has focused prescription drug use, management, outcomes and policies. The research group has developed and utilized a number of large and rich research databases to support research in all of these critical areas. Dr. Crystal鈥檚 work over the years in both academic and non-academic settings has addressed a range of key issues in state and local health policy; he has worked extensively on the delivery of health care services through state Medicaid programs. His research and publications in the aging area include work on economic well-being of the elderly; long-term care of older people; insurance status and the impact of out-of-pocket health care costs; Medicare policy; and pharmaceutical drug policies for lower income elderly. He heads a team of investigators addressing HIV health services delivery issues. His research group has developed the capacity to carry out detailed studies of Medicaid health care utilization and outcomes using claims and other administrative files and has applied this expertise to a series of studies funded by the Agency for Health Care Policy and Research and Quality (AHRQ), the National Institute of Drug Abuse, the National Institute of Mental Health (NIMH), the National Institute on Aging, HHS鈥檚 Assistant Secretary for Planning and Evaluation, the Commonwealth Fund, and other agencies and foundations. He currently heads an NIMH-funded national study of treatment for geriatric depression. His more than 200 publications include books on old-age policy and on home health care, and research articles, reviews and technical reports addressing a wide range of issues in old-age policy, health services research, long-term care for the elderly, pharmaceutical use, mental health services, and other topics related to healthcare and aging. He is a frequent advisor to federal, state and international health agencies and has served on numerous study sections and peer reviews. He has served as Visiting Professor of Health Care Policy at Harvard Medical School鈥檚 Department of Health Care Policy and as Chief of the Division of Health Care Sciences at the School of Medicine, University of California, San Diego. During the late 1970s and early 1980s, he held a variety of senior positions in health services delivery in New York City government, managing major health and human services programs, and created and headed the Center for Human Services Research and Development, which conducted national studies in areas including home care and adult protective services. He has also served as an Urban Fellow in New York City鈥檚 Office of the Mayor, and consultant at the City鈥檚 Office of Management and Budget. His awards include the Abt Associates Prize for Public Policy Research and the John Kendrick Award for research on the economic status of the elderly.

Daniel Horton (MSCE, Clinical Epidemiology, University of Pennsylvania, 2015; MD, Harvard Medical School, 2008; AB, Harvard College, 2001) is an Assistant Professor in the Department of Pediatrics, Divisions of Pediatric Rheumatology and Population Health, Quality, and Implementation Sciences (PopQuIS), at Rutgers Robert Wood Johnson Medical School, and the Department of Biostatistics and Epidemiology at the Rutgers School of Public Health. He is a core member of the Rutgers Center for Pharmacoepidemiology and Treatment Science at the Institute for Health, Health Care Policy and Aging Research and a Chancellor鈥檚 Scholar at Rutgers Biomedical and Health Sciences. Dr. Horton鈥檚 research focuses on the uses, safety, and effectiveness of medications in pediatric populations, and the origins and management of childhood arthritis. He performs epidemiologic studies using large administrative and electronic health records databases as well as translational research. He has been involved in efforts to understand the risk factors and impact of the coronavirus pandemic and COVID-19 in children and adults, with a focus on health care workers. His research has been funded by the National Institutes of Health and various research foundations.

Joel C. Cantor (Sc.D., Johns Hopkins University) is a Distinguished Professor of Public Policy and the Founding Director of the Center for State Health Policy at Rutgers University in New Brunswick, New Jersey. Established in 1999, the Center is a leader in health policy research and development nationally, with a special focus on informing policy in New Jersey. Dr. Cantor is published widely in the health services and policy literature on innovations in health service delivery and the regulation of private health insurance markets. He serves frequently as an advisor on health policy matters to New Jersey state government, and was the 2006 recipient of the Rutgers University President鈥檚 Award for Research in Service to New Jersey. In June 2017, Dr. Cantor was appointed Interim Director of the Rutgers Institute for Health, Health Care Policy and Aging Research. The Institute is the parent unit of the Center for State Health Policy and other centers and programs addressing critical health and mental health issues. Prior to joining Rutgers in 1999, Dr. Cantor served as director of research at the United Hospital Fund of New York and director of evaluation research at the Robert Wood Johnson Foundation. He received his doctorate in health policy and management from the Johns Hopkins University, School of Public Health in 1988, and was elected a Fellow of AcademyHealth in 1996.

Pietro Tonino, MD, MBA, was drawn to orthopaedics in part because of his love of sports, and he now works extensively with professional, college and recreational athletes. Over the years his team of orthopaedic and sports medicine physicians have increasingly seen more ACL and other injuries in young women. Dr. Tonino received his medical degree from Northwestern University Feinberg School of Medicine and completed his residency at Northwestern University McGaw Medical Center. He completed a fellowship in orthopaedic surgery and sports medicine at Kerlan-Jobe Orthopaedics. 

Ph.D., Harvard University, 2010 
B.S., New York University, 2002
NSF ACC Postdoctoral Fellow, Caltech, 2010-2013

Research Interests
Origin-of-Life/Prebiotic Chemistry, Organic Chemistry, Inorganic Chemistry

Don Moore is the Lorraine Tyson Mitchell Chair in Leadership and Communication at Berkeley Haas. He received his PhD in Organization Behavior from Northwestern University. His research interests include overconfidence鈥攊ncluding when people think they are better than they actually are, when people think they are better than others, and when they are too sure they know the truth. He is only occasionally overconfident.

Expertise and Research Interests:

Ethical Choice
Decision-Making
Overconfidence
Negotiation

Positions Held:

2016 鈥� present, Professor, Management of Organizations Group, Haas School of Business
2010 鈥� 2016, Associate Professor, Management of Organizations Group, Haas School of Business
Courtesy appointment in the Department of Psychology, University of California, Berkeley
2015 鈥� present, Faculty Director, Xlab
2000 鈥� 2010, Assistant to Associate Professor of Organizational Behavior, Tepper School of Business, Carnegie Mellon University

Professor of Economic Analysis and Policy and Finance

Expertise and Research Interests:

Small Business Lending
Bank Mergers and Acquisitions
Banking
Business Conditions
Consumer Spending
Unemployment And Inflation
Federal Reserve Monetary Policy And Interest Rates
Credit Union Failures And Losses

Positions Held:

1978 鈥� present, Professor, Haas School of Business
2016 鈥� present, Member, Financial Economists Roundtable
2014 鈥� 2016, Member, Board of Directors, VirtualBeam, Inc.
2012 鈥� present, Member, Board of Directors, Finance Scholars Group
2012 鈥� 2015, Chair, Economic Analysis and Policy Group, Haas School of Business
2003 鈥� present, Fellow, Wharton Financial Institutions Center
1999 鈥� 2001, Chief Economist, Office of the Comptroller of the Currency, Washington, DC
1991 鈥� 1992, Economist, Federal Reserve Board
1990 鈥� 1991, Senior Economist, President鈥檚 Council of Economic Advisers

Dr. Gary Kleiner, MD is an Allergy & Immunology Specialist in Miami, FL, and has over 25 years of experience in the medical field.  He graduated from SUNY Downstate M C Coll Med medical school in 1995.

Dr. Laura Beauchamps is an Infectious Disease Specialist in Miami, Florida. She graduated with honors in 2001. Having more than 19 years of diverse experiences, especially in INFECTIOUS DISEASE, INTERNAL MEDICINE, Dr. Laura Beauchamps affiliated with many hospitals including Jackson Health System, University Of Miami Hospital And Clinics, cooperates with many other doctors and specialists in the medical group the University Of Miami.

Prof. Dushyantha Jayaweera MD, FACP, MRCOG (UK), CIP is a Professor in Clinical Medicine at the University of Miami Miller School of Medicine. He graduated from the University of Colombo, Sri Lanka, and has been working on HIV for the last 25 years. He has received grant support from the National Institutes of Drug Abuse, National Institute of Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Disease, and the National Science Foundation. Dr. Jayaweera has led and continues to lead numerous industry-funded trials of HIV and HIV/HCV coinfection and has published extensively. He was formerly the Associate Vice Provost for Human Subject Research overseeing the activities of the ethics committees. He received his M.D. degree in Sri Lanka and trained in medicine in Sri Lanka, Great Britain, and the Loyola University of Chicago. In conjunction with other esteemed faculty members at UM, he has been instrumental in initiating minority HIV and HIV/HCV care clinics in the US. Prof. Jayaweera is a frequent speaker and organizer of international workshops, meetings, and conferences.

Susan R. Bailey, MD, an allergist/immunologist from Fort Worth, Texas, was elected president of the American Medical Association in June 2020. Previously, she served as president-elect of the AMA for one year, speaker of the AMA House of Delegates for four years and as vice speaker for four years.

Dr. Bailey, who has been active in the AMA since medical school when she served as chair of the AMA Medical Student Section, has held numerous leadership positions with the AMA. These include serving as chair of both the Advisory Panel on Women in Medicine and the AMA Council on Medical Education, as well as representing the AMA on the Accreditation Council for Continuing Medical Education, the American Board of Medical Specialties, and COLA.

Her long history of service in helping guide organized medicine extends to the local and state levels as well. She has served as board chair and president of the Tarrant County Medical Society, and as vice speaker, speaker and president of the Texas Medical Association.

Dr. Bailey is an allergist in private practice, and has been with Fort Worth Allergy and Asthma Associates for over 30 years. She completed her residency in general pediatrics and a fellowship in allergy/immunology at the Mayo Graduate School of Medicine in Rochester, Minn., and is board certified in allergy and immunology, and pediatrics and has been awarded the title of Distinguished Fellow of the American College of Allergy, Asthma, and Immunology.

In addition to receiving her medical degree with honors from the Texas A&M University College of Medicine
as a member of its charter class, Dr. Bailey was later appointed to the Texas A&M System Board of Regents by then Gov. George W. Bush, and has been named a Distinguished Alumnus of Texas A&M University and of Texas A&M University College of Medicine.

Dr. David Price 鈥� Professor and Chair of the Department of Family Medicine at McMaster University since 2006 and was Chief of Family Medicine at Hamilton Health Sciences from 2004-2018. While most of his career has been as a comprehensive family physician in major urban centres (including Vancouver and Hamilton), he is proud of the fact that he gained significant clinical experience in a number of rural and northern communities. During his tenure as Chair, the Department has experienced substantial growth such that it now graduates over 100 family medicine residents annually, has a full-time faculty of over 40 with approximately 1,400 part-time faculty and 200 staff. The total Department budget overseen is now just under $40 M annually. The research enterprise within the department has also grown proportionately, with approximately $19 M managed annually and is recognized both nationally and internationally for its work in primary care.

Through his leadership roles at the University and Hospital, and his involvement with local, regional, and provincial government bodies where he acts as a consultant and advisor, he has developed expertise in primary care reform and health care policy development. As the Chair of the Provincial (Ontario) Expert Advisory Panel on Primary Care (2013-2014) he was instrumental in helping produce 鈥淧atient Care Groups: A new model of population based primary health care for Ontario鈥� (鈥淧rice Report鈥�). Locally, he was the founding director of the Maternity Centre of Hamilton; a multidisciplinary centre that cares for prenatal and intrapartum patients. Dr. Price was also instrumental in helping to create the academic Family Health Team at McMaster University, an interprofessional team, currently serving over 40,000 patients in the Hamilton area. He was a key player in the development of the $85 M, David Braley Health Sciences Centre, a six-story, 185,000 sq. ft. home for Family Medicine and Hamilton Public Health in the downtown core. He has participated in over $6M in peer reviewed research funding (> $1M as lead) and has been the lead in over $15 M of other funding from a variety of Governments and Agencies. David has authored over 35 peer reviewed publications (half of these as either lead or senior author) and published numerous other articles/book chapters.

In April 2020, during the Covid-19 pandemic, he was tasked with chairing the Primary Care Advisory Table on behalf of Ontario鈥檚 Ministry of Health.